Neoantigen Cancer Vaccine Helps BioNTech Advance Oncology Ambitions
Encouraging 50% Response Rate
After many years of failures and setbacks, neoantigen-targeting immunotherapies are gaining momentum, with BioNTech and Roche among the frontrunners.
After many years of failures and setbacks, neoantigen-targeting immunotherapies are gaining momentum, with BioNTech and Roche among the frontrunners.